Results 231 to 240 of about 27,004 (255)

Myelodysplastic syndrome overview

Seminars in Hematology, 2002
Myelodysplastic syndrome (MDS) is a heterogeneous hematopoietic stem cell disorder characterized by bone marrow dysplasia and peripheral cytopenias. Eighty percent of patients found to have MDS are older than 60 years and therefore not eligible for the only potentially curative therapy, bone marrow transplantation.
openaire   +2 more sources

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆

Annals of Oncology, 2021
Pierre Fenaux, Valeria Santini, U Mey
exaly  

The myelodysplastic syndrome

European Journal of Cancer and Clinical Oncology, 1990
openaire   +2 more sources

Myelodysplastic Syndromes

Scottish Medical Journal, 1994
P G, Cachia, R A, Padua
openaire   +2 more sources

Therapy with azanucleosides for myelodysplastic syndromes

Nature Reviews Clinical Oncology, 2010
Fabio P S Santos, Guillermo Garcia-Manero   +1 more
exaly  

Health care utilization and mortality among elderly patients with myelodysplastic syndromes

Annals of Oncology, 2011
Mark D Danese, J Mikhael
exaly  

Decitabine in the treatment of myelodysplastic syndromes

Expert Review of Anticancer Therapy, 2010
Fabio P S Santos, Hagop Kantarjian, Guillermo Garcia-Manero   +2 more
exaly  

Telomere length in myelodysplastic syndromes

Leukemia and Lymphoma, 2011
Rami S Komrokji, Dana E Rollison, William J Fulp   +2 more
exaly  

Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes†

Annals of Oncology, 2014
Francesco Cottone, Gianluca Gaidano, Maria T Voso   +2 more
exaly  

Remicade as TNF Suppressor in Patients with Myelodysplastic Syndromes

Leukemia and Lymphoma, 2004
Anna Candoni, S Gezer
exaly